Introduction
Viruses that undergo a lytic replication cycle selectively in malignant cells form a promising new class of anticancer agent. 1 The adenovirus (Ad) mutant dl1520 2 was engineered not to express the E1B-55K protein, an important function of which is to inactivate the tumour suppressor protein p53, thereby preventing p53-mediated cell cycle arrest or apoptosis during infection of normal human cells and thus allowing efficient virus replication. Ad dl1520, also known as Onyx-015, is therefore severely restricted in its ability to replicate in normal cells, whereas its replication in malignant cells, in which the p14 ARF -p53 pathway is usually dysfunctional, is relatively unimpeded. 3, 4 Onyx-015 has been tested in a number of clinical trials, involving single or multiple direct intratumoral injections, intravenous, intrahepatic arterial or intraperitoneal delivery to cancers of the head and neck, pancreas, ovary and liver metastases of colorectal cancer; many of these trials were reviewed by Kirn. 5 While the virus was shown to be safe by all these routes of delivery, and at doses of up to 2 Â 10 12 particles, efficacy as a single agent was low. However, when Onyx-015 was used in combination with chemotherapy, the modalities appeared to work synergistically. A number of tumour nodules that had previously progressed on chemotherapy alone demonstrated complete regression and extended time to recurrence following virus injection and concurrent systemic administration of cisplatin and 5-fluorouracil. 5, 6 The combination of chemotherapy with dl1520 virotherapy delivered via the hepatic artery also produced some responses of colorectal cancer liver metastases that had previously progressed on either chemotherapy or virotherapy alone. 7 The localized activation of nontoxic prodrugs to cytotoxic derivatives by enzymes within a tumour has the potential to achieve superior antitumour efficacy without the systemic, dose-limiting toxicity associated with conventional chemotherapeutic agents. 8 A favoured modality of cancer gene therapy involves using viral vectors to express prodrug-activating enzymes in tumour cells. Thus, expression of thymidine kinase from herpes simplex virus (HSV-TK) sensitizes the infected cells to the prodrugs acyclovir and ganciclovir (GCV); 9 expression of cytosine deaminase from Escherichia coli or yeast sensitizes cells to 5-fluorocytosine (5-FC); 10, 11 and cells expressing E. coli nitroreductase (NTR) are sensitized to the prodrug CB1954 (5-[aziridin-1-yl]-2,4-dinitrobenzamide). [12] [13] [14] Many of the reported studies with these systems have employed replication-defective adenovirus vectors, due to their high titre and efficient gene delivery to many cell types irrespective of cell proliferation status. Each system exhibits a bystander effect, whereby localized spread of activated prodrug from cells in which it is generated can kill other cells in the vicinity that do not themselves express the enzyme. Nevertheless, the limitations on the amount and distribution of virus delivery to intact tumours in vivo reduces the efficiency of tumour therapy in animal models below that which can be achieved when all tumour cells endogenously express the enzyme.
There could be considerable benefits from combining these approaches, using a conditionally replicative adenovirus to express prodrug-activating enzymes in tumour cells. Relative to a replication-defective vector, the increased gene copy number due to virus replication should increase the expression of the prodrug-activating enzyme selectively in the malignant cells, while the potential for multiple cycles of spread beyond the initially infected cells could improve the distribution of virus and prodrug-activating enzyme within the tumour. The demonstrated synergy of combining conventional chemotherapy with oncolytic virotherapy predicts a greater benefit from combination of localized prodrug activation with oncolytic virotherapy. Wildner et al 15, 16 have generated an E1B-55K-deleted adenovirus expressing HSV-TK. Intratumoral injection of this virus, in combination with GCV treatment, slowed the growth of tumour xenografts and prolonged survival of the mice. Freytag et al 17 incorporated a CD/TK fusion gene in an E1B-55K-deleted adenovirus. In several tumour cell lines in vitro, addition of a single prodrug enhanced the oncolytic activity, although exceptions were noted. In vivo, addition of both prodrugs following virus administration resulted in marked tumour regression and growth delay, which could be further enhanced by combination with radiotherapy. 18 The ultimate cytotoxic products generated from the prodrugs GCV or 5-FC are nucleotide analogues that inhibit DNA synthesis. In contrast, activation of CB1954 generates a potent DNA-crosslinking agent whose cytotoxicity is independent of ongoing DNA replication. 12, 19, 20 Treatment of mice with CB1954 can lead to complete regression of tumour xenografts that stably express NTR following in vitro retroviral transduction 21 or transfection. 22 Tumour regression and prolonged survival have also been observed following in vivo delivery of replication-defective adenovirus expressing NTR and treatment with CB1954. 20, 23 However, the antitumour efficacy was suboptimal and dependent on virus dose, which was limited by systemic toxicity. We anticipated that use of a replicating vector could improve the efficacy of the system, and report here the construction and evaluation, both in vitro and in vivo, of an E1B-55K-deleted, conditionally replicating adenovirus expressing NTR (CRAd-NTR(PS1217H6)).
Results
In CRAd-NTR(PS1217H6) (Figure 1 ), the NTR gene is inserted at the site of E1B-55K deletion, under the transcriptional control of the CMV immediate-early promoter, and followed by an intron and 3 0 -end processing signals from human b-globin and complement C2 genes, respectively, as previously described. 20, 23 This NTR expression cassette is similar to that in CTL102, 23 a fully E1-deleted, replication-defective adenovirus currently in clinical trials. 24 In CRAd-NTR(PS1217H6), we inserted the 3 0 end of the bovine growth hormone gene immediately downstream of the E1B-19K coding region to reduce possible transcriptional interference with the inserted transgene.
We also produced a similar construct, CRAd-EGFP(PS1217L), carrying the gene for enhanced green fluorescent protein (EGFP) (Clontech) instead of NTR. This was used to check the infectability of the colorectal carcinoma cell lines, SW480 and WiDr, infected at multiplicities of 0.5, 5 or 10 plaque forming units (PFU)/cell. The percentage of cells expressing EGFP was determined by flow cytometry 24, 48 and 72 h after infection ( Table 1 ). The replication-defective virus, Ad-CMV-EGFP, was also used for comparison. This established that a multiplicity of 5-10 PFU/cell was sufficient to infect the majority of cells in these two lines.
Replication of CRAd-NTR(PS1217H6)
The ability of CRAd-NTR(PS1217H6) to cause cytolysis of malignant and nontransformed cells as a result of viral replication was compared with Ad5-WT. The two colorectal carcinoma cell lines SW480 and WiDr, and the Figure 1 Map of CRAd-NTR(PS1217H6). The E1A and E1B19K genes are derived from dl1520. bGH 3 0 , 3 0 end of bovine growth hormone gene; CMV, cytomegalovirus immediate-early promoter; NR, NTR coding region; bG/C2, splice sites and second intron from human b-globin and 3
0 -end signals from human complement C2 gene. The numbers correspond to the Ad5-WT sequence. (Figure 2a ). In the tumour cell lines, oncolysis equivalent to Ad5-WT at 1 PFU/cell was observed with 10 PFU/cell of CRAd-NTR(PS1217H6).
In the normal KS fibroblasts, equivalence was obtained with 50 PFU/cell CRAd-NTR(PS1217H6), while in the AC3 keratinocytes even 100 PFU/cell of CRAd-NTR(PS1217H6) caused only partial lysis of the cell sheet.
In a separate experiment, SW480, KS and AC-3 cells were infected with 0, 0.1, 1, 10 or 100 PFU/cell of CRAd-NTR(PS1217H6). All were stained with crystal violet when the SW480 cultures infected with 1 PFU/cell showed complete oncolysis, 14 day after infection. At this time, the KS cell cultures were eliminated at 100 PFU/cell, but showed no growth inhibition at 10 PFU/cell. The AC-3 keratinocytes showed just partial cytolysis at 100 PFU/cell (Figure 2b ).
The time course of virus DNA replication was monitored following infection of SW480 cells with 0.5 PFU/cell of CRAd-NTR(PS1217H6). DNA was extracted, dot-blotted and probed with a 32 P-labelled probe from the E4 region of the virus. As shown in Figure 3a , virus DNA was below the threshold of detection at 12 h, but gave a distinct signal at 24 h with increasing intensity at 36 and 48 h. No signal was detected at any time point from parallel cultures infected with the E1-deleted, replication-defective adenovirus CTL102. The signal for CRAd-NTR(PS1217H6) was quantitated using a phosphoimager, in comparison with a standard curve. The DNA levels at 24, 36, 
Comparison of NTR expression
An expected benefit of a replicating vector is that the increased gene copy number could lead to a substantial increase in the level of transgene expression, compared to the equivalent replication-defective vector. To confirm this and establish the time course, total protein samples were prepared from cultures of SW480 or WiDr cells infected with 10 PFU/cell of CRAd-NTR(PS1217H6) or CTL102, and levels of NTR were monitored by Western blot. As shown in Figure 4 , NTR was just detectable at 12 h following infection with CRAd-NTR(PS1217H6), and increased rapidly to a strong maximum signal by 48 h. Levels of NTR expressed by CTL102 increased much more gradually throughout the time course; in SW480 cells, the signal at 24 h was comparable to that from CRAd-NTR(PS1217H6) at 12 h post infection, and even by 96 h the expression from CTL102 was much weaker than that from CRAd-NTR(PS1217H6) at 24 h. Similar results were obtained in WiDr cells.
Effect of prodrug activation on virus replication
We investigated the potential impact of CB1954 exposure on the generation of infectious progeny virus. SW480 cells were infected with 10 PFU/cell CRAd-NTR(PS1217H6), then exposed to 2 or 10 mM CB1954 commencing 2, 24 or 48 h after infection. The cultures were harvested at 72 h post infection, and the titre of CRAd-NTR(PS1217H6) was determined by plaque assay. As shown in Figure 5 , the yield of infectious virus was reduced by about 50-or 500-fold by 2 or 10 mM CB1954, respectively, when prodrug was added 2 or 24 h after infection. In these conditions, the recovered virus was less than the input dose. Delaying addition of prodrug until 48 h post infection caused smaller reductions in titre relative to control cultures not treated with CB1954, and a modest increase over the input dose (1.5-and 4-fold, at 10 or 2 mM CB1954, respectively). This could be due in part to the shorter overall duration of CB1954 exposure, but also correlates with the time course of replication shown in Figure 3 , in which the peak period of virus replication is 24-48 h post infection. We conclude that to obtain optimum benefit of viral replication in addition to the suicide gene therapy, addition of prodrug should be delayed until at least 48 h following infection.
Cell killing by combination of prodrug activation with viral oncolysis SW480 cells were infected with CRAd-NTR(PS1217H6) at 5 PFU/cell, or CTL102 at 5 and 100 PFU/cell. After 48 h, CB1954 was added to the cultures at a range of concentrations, and cell viability was determined 4 days later by MTS assay. As shown in Figure 6a , CTL102 at 5 PFU/cell resulted in at most 10% reduction in viable cell number, at the highest prodrug concentration (100 mM CB1954); this was similar to the killing of uninfected cells at this prodrug concentration (not shown). The oncolytic effect of CRAd-NTR(PS1217H6) in the absence of prodrug resulted in 11% reduction in viable cells. The combination with prodrug resulted in 47, 71 and 93% loss of cell viability at 5, 10 and 20 mM CB1954, respectively. These levels of prodrug-dependent cell killing were greater than achieved using a 20-fold higher dose of the replication-defective virus CTL102. However, CTL102 was more effective in combination with CB1954 than the parental oncolytic virus dl1520; in a separate experiment, 490% of SW480 cells infected with CTL102 at 20 or 50 PFU/cell were killed at 100 mM CB1954 (50% cell killing at 25 and 5 mM CB1954, Oncolytic adenovirus expressing nitroreductase M-J Chen et al respectively) whereas the equivalent doses of dl1520 killed only B20-45% of the cells at 100 mM CB1954 (results not shown). Thus the enhanced cell killing by the combination of CRAd-NTR(PS1217H6) and CB1954 is due to the expression of NTR able to activate the prodrug.
In WiDr cells (Figure 6b ), almost 40% reduction in cell viability was seen with 5 PFU/cell CRAd-NTR(PS1217H6) in the absence of prodrug; this increased to B70% reduction with 20 mM CB1954, whereas 5 PFU/ cell CTL102 caused only 13% reduction in viability at 20 mM CB1954. The combined effects of oncolysis and prodrug activation with CRAd-NTR(PS1217H6) at 5 PFU/cell were greater than the cell killing caused by CB1954 plus CTL102 at 25 PFU/cell (Figure 6b ).
In vivo studies with CRAd-NTR(PS1217H6)
To investigate the replication of CRAd-NTR(PS1217H6) in vivo, subcutaneous SW480 tumour xenografts were established in nude mice. When the tumours reached 5-8 mm in diameter, they were injected with 2 Â 10 8 PFU of either CRAd-NTR(PS1217H6) or CTL102. Tumours were harvested 12 and 72 h later and analysed for replication of vector DNA and for NTR expression. Virus DNA was analysed by quantitative PCR. As shown in Figure 7a , low and variable levels of virus DNA were detected at 12 h; however, the mean level of CRAd-NTR(PS1217H6) was slightly higher than CTL102 (0.2870.28 versus 0.170.09 ng/tumour, corresponding to B7.2 and 2.8 Â 10 6 genome copies, respectively). By 72 h after injection, the level of CRAd-NTR(PS1217H6) DNA had increased B500-fold to 138713.8 ng (B3.8 Â 10 9 copies).
More surprisingly, even the E1-deleted CTL102 virus DNA had increased B85-fold, to 8.4276.46 ng DNA (B2.3 Â 10 8 copies). This is unlikely to be due to contaminating, replication-competent adenovirus (RCA) since no cytopathic effects were observed, and minimal replication could be measured, in vitro (see above). Also, quantitative PCR analysis of the stocks of CTL102 established an upper limit of one copy of E1A sequence (potentially representing RCA) per 0.9-5.3 Â 10 5 virus particles, which could not account for the level of replication detected.
It has been reported previously that at high multiplicities of infection, E1-deleted adenoviruses can replicate their DNA in a variety of human tumour cell lines, in a dose-and cell cycle-dependent manner. 25 This effect would be negligible in our in vitro experiments, which used a maximum of 10 PFU/cell; however, following injection of 2 Â 10 8 PFU into a tumour, inevitably cells close to the injection site may be infected at much higher multiplicities, facilitating such E1-independent virus replication. Nevertheless, the CRAd replicated to levels B15-fold higher than CTL102 in the tumours.
NTR expression in the tumours was monitored by Western blotting (Figure 7b) . A detectable level of NTR was produced in the CTL102-injected tumour at 12 h, and the intensity of the signal increased by 72 h after injection. The signal from tumours injected with CRAd-NTR(PS1217H6) also increased substantially between 12 and 72 h after injection, and even at 12 h the level of NTR was greater than that expressed by CTL102 at 72 h. (Figure 8a and b) . By 7 days after virus injection, NTR expression in tumours injected with CTL102 appears substantially reduced from day 3 with relatively few, scattered cells showing convincing NTR expression (Figure 8c and d) . On day 7, there appears markedly more NTR expression in tumours injected with CRAd-NTR(PS1217H6) than with CTL102, although this may still represent a decline since day 3 ( Figure 8g and h) ; it is possible that viral oncolysis could have contributed to this decline. Adenovirus structural proteins, which are only expressed late in the replication cycle, were also monitored; Figure 8j shows strong staining for adenovirus structural proteins in tumour cells 7 days after injection of CRAd-NTR(PS1217H6), which colocalized with expression of NTR in adjacent sections (Figure 8i ). Adenovirus proteins were not detectable in tumours injected with CTL102 (not shown). Thus, although the initial distribution of NTR expression within the tumours was similar with both the replication-defective and conditionally replicative viruses, the combined data from Western blotting and immunohistochemistry indicate that considerably more NTR is produced, and the duration of high expression is greater, in tumours infected with the oncolytic CRAd-NTR(PS1217H6) than in those infected with CTL102.
To compare the therapeutic efficacy of CRAd-NTR(PS1217H6) with CTL102, subcutaneous SW480 tumour xenografts 5-8 mm in diameter were injected on each of 5 consecutive days with 2 Â 10 8 PFU of the viruses, or PBS as a control. This regimen was based on the findings of Heise et al 26 that injecting Onyx-015 (dl1520) on 5 successive days was more effective than the same total dose delivered on a single occasion. Subsequently, each group of mice was further subdivided, with half of the animals receiving intraperitoneal injections of CB1954 (25 mg/kg) on 4 successive days, the others receiving the PBS vehicle. Prodrug treatment was commenced 48 h after the last virus injection, to allow maximum NTR expression even from the last virus injection (see Figure 4) . Although Figure 5 suggests this will reduce the potential yield of infectious progeny virus, at least from the last injection, Figure 3 suggested the replication cycle should be almost complete, and the interval since the earlier virus injections is correspondingly longer (up to 6 days). Figure 9 shows the average tumour volumes for each experimental group plotted over the 35 days following the initial virus injections. The control, untreated tumours grew at the fastest rate over this time, so that by day 35 several of the mice had to be culled due to tumour size; the average tumour size (7s.e.m.) of this group at 35 days was 16487227 mm 3 . The group treated with CB1954 alone showed some reduction in tumour growth, (10177146 mm 3 on day 35, P ¼ 0.0375). Tumours injected with the replication-defective virus CTL102 had an average volume of 7847210 mm 3 in the absence of prodrug, which was reduced to 6127103 mm 3 for the group also treated with CB1954. Tumours injected with CRAd-NTR(PS1217H6) had average sizes of 6177165 and 311754 mm 3 in the absence and presence of CB1954 treatment, respectively. The reductions in tumour volume caused by both CTL102 and CRAd-NTR(PS1217H6) in the absence of prodrug were Oncolytic adenovirus expressing nitroreductase M-J Chen et al significant (P ¼ 0.0149 and 0.0032, respectively), and the combination treatments of CTL102 or CRAd-NTR(PS1217H6) with CB1954 both caused significant reductions in tumour growth, relative to CB1954 alone (P ¼ 0.0425 and 0.0007, respectively). The oncolytic virus CRAd-NTR(PS1217H6) was significantly more effective than CTL102 in the presence of CB1954 (P ¼ 0.0238).
The survival data are shown in Figure 9b . The median survival times for groups injected with PBS, CTL102 or CRAd-NTR(PS1217H6) were 42, 75 and 78 days respectively without CB1954, and 62, 72 and 81 days respectively with CB1954 treatment. The prolonged survival due to CB1954 without either virus was significant (P ¼ 0.01). In the absence of prodrug, both viruses significantly prolonged survival compared with untreated tumours (P ¼ 0.0009 and 0.003 for CTL102 and CRAD-NTR(PS1217H6), respectively), while among the CB1954-treated groups, the increased survival mediated by CRAd-NTR(PS1217H6) was significant (P¼0.0086) whereas that mediated by CTL102 was borderline (P ¼ 0.0896).
Discussion
Clinical trials are underway of CTL102, a replicationdefective adenovirus expressing NTR from the CMV promoter, in combination with CB1954. 23, 24, [27] [28] [29] Relative to this virus, CRAd-NTR(PS1217H6) was expected to deliver improved efficacy due to increased expression of NTR, improved spread within the tumour, and synergy between viral oncolysis and the cytotoxicity of activated prodrug.
Initial studies investigating the replicative properties of CRAd-NTR(PS1217H6) showed it to be strongly attenuated relative to Ad5-WT in nontransformed human cells, requiring around 50-100 times higher infection doses to achieve equivalent lysis of primary fibroblasts (KS) and AC-3 keratinocytes. In the colorectal cancer cell lines SW480 and WiDr, although CRAd-NTR(PS1217H6) is still attenuated relative to Ad5-WT, the differential is no more than 10-fold. Thus, as with the prototypic E1B-55K-deleted adenovirus dl1520, CRAd-NTR(PS1217H6) is oncolytic, that is, demonstrates the ability to replicate and spread in cancer cells while being strongly attenuated in normal or nontransformed cells. Although the molecular basis for this effect has transpired to be more complex than was initially proposed, 4, 30, 31 the established safety record of dl1520 in clinical trials commended this basic design of the vector. An additional safety feature is that insertion of the CMV-NTR expression cassette at the site of E1B-55K deletion ensures that if, by recombination with E1 sequences in complementing cell lines or Ad5-WT, the virus were to acquire a functional E1B-55K gene, and hence full replication-competence, this would lead to concomitant deletion of the transgene, preventing the generation of a fully replication-competent virus carrying the transgene.
By 72-96 h following infection of SW480 and WiDr colorectal carcinoma cell lines in vitro with CRAd-NTR(PS1217H6), the titre of infectious virus rose by 3-4 orders of magnitude, consistent with the observed increase in virus DNA and corresponding to B18-to 57-fold amplification of the input virus. Similarly in vivo, a large increase in the amount of CRAd-NTR(PS1217H6) DNA was observed between 12 and 72 h following intratumoral injection of the virus. In vivo, the DNA of E1-deleted vector CTL102 replicated to a level approximately one-fifteenth that achieved by CRAd-NTR(PS1217H6). Although unanticipated, replication of E1-deleted vectors has been reported previously in a variety of tumour cell lines; this depended on the number of viral genomes present in the cell nucleus, but standardized infection conditions used from 50 to 1500 PFU/cell, for different cell lines. 25 Although our in vitro experiments used a maximum of 10 PFU/cell, intratumoral injection of 2 Â 10 8 PFU would result in many cells taking up sufficient CTL102 to allow such E1-independent replication. It is interesting to speculate that this could be responsible for the prodrug-independent antitumour effects of CTL102 seen in Figure 9 . Nevertheless, the replication of CRAd-NTR(PS1217H6) was significantly greater, and able to occur at low multiplicities of infection, accounting for the oncolytic action of this virus in vitro and its greater efficacy at slowing tumour growth in vivo.
As predicted, CRAd-NTR(PS1217H6) gave substantially higher levels of NTR expression relative to CTL102 both in vitro and in vivo. In vitro, 5 PFU/cell of CRAd-NTR(PS1217H6) resulted in greater sensitization of SW480 cells to CB1954 than 100 PFU/cell of CTL102. The increased NTR expression from the replicating Oncolytic adenovirus expressing nitroreductase M-J Chen et al vector and increased sensitization to CB1954 were also seen in WiDr cells, although in this case viral oncolysis alone caused significant cell loss within the timescale of the experiment. When the data are normalized relative to cell survival in the presence of the virus but absence of prodrug, CRAd-NTR(PS1217H6) provided sensitization to CB1954 comparable to a five-fold greater dose of CTL102 in WiDr cells. Thus enhanced killing of both tumour cell lines was obtained by the combination of CB1954 prodrug activation and oncolytic replication of the vector. Preliminary data (not shown) suggest that nontransformed cells are relatively resistant to the combination of CRAd-NTR(PS1217H6) and CB1954.
In vivo, the combination of CRAd-NTR(PS1217H6) and CB1954 was the most effective treatment for subcutaneous SW480 tumour xenografts, the treated tumour volume growing just 2.8-fold over the 5 weeks following start of treatment, compared to an increase of 13.5-fold in untreated tumours over the same period. Treatment with CB1954 alone caused a modest reduction (8.5-fold growth); this might be due to expression of DT diaphorase, which is often upregulated in human cancers and can activate CB1954, albeit inefficiently. 32 Tumours treated with CRAd-NTR(PS1217H6) without prodrug grew five-fold, while tumours treated with CTL102 plus prodrug grew 5.4-fold. This benefit of combining viral oncolysis with CB1954 activation was also reflected in the survival analysis of the mice, with animals receiving CRAd-NTR(PS1217H6) and CB1954 having the longest median survival, and being the only treatment group to achieve significantly longer survival than mice treated with CB1954 alone.
Both HSV-TK and a CD/TK fusion gene have previously been shown to improve the antitumoral efficacy of E1B-55K-deleted oncolytic adenoviruses, when used in conjunction with their respective prodrugs. In xenograft models using HT29 colon carcinoma, A375 melanoma and ME180 cervical carcinoma, the oncolytic virus expressing TK alone provided B1.5-to 3-fold increase in median survival, while combination with GCV treatment (initiated 3 days after virus injection) increased the differential to B3.5-to 45-fold compared to untreated controls. 15, 16 In C33A cervical carcinoma xenografts, the oncolytic adenovirus expressing the CD/ TK fusion gene gave a 20-day growth delay, which was not significantly extended by either prodrug alone, but the combination with both GCV and 5-FC extended this B3-fold. 18 Additional use of radiotherapy resulted in a further marked improvement in growth delay. 18 Thus the principle of improved efficacy from combining oncolytic viruses with prodrug activation, already established for antimetabolite prodrugs, has been extended to an alkylating agent prodrug, and it may be anticipated that further combinations between CRAd-NTR(PS1217H6)/ CB1954, and TK/GCV, CD/5-FC, or radiotherapy could show further benefit. Our previous work suggests that NTR/CB1954-induced cell death also contributes to an antitumour immune response and such an effect could be further enhanced in the context of an oncolytic virus, providing an additional immune bystander effect. 33 CB1954 exposure of cells infected with CRAd-NTR(PS1217H6) led to a reduction in the yield of virus progeny ( Figure 5 ). Similar effects have also been observed on the replication of CRAds expressing TK or CD, when treated with their respective prodrugs. These effects are not unexpected, and are indeed a safety feature, allowing termination of virus replication if required. 16, 17 Clearly, the timing of prodrug administration will be a key factor in the overall efficacy; administration too early in the course of oncolytic infection could be counterproductive, preventing virus replication and thus limiting both the oncolyic effect, and the amount and distribution of the prodrug-activating enzyme. However, with optimum timing, prodrug activation is expected to kill more cells, or do so more rapidly while the tumour is smaller, than could be achieved by viral oncolysis alone. Indeed, Figure 9 shows a clear benefit in combining the modalities. Theoretically, prodrug activation might even enhance spread of the oncolytic virus, if direct and bystander cell killing allowed more efficient release and dissemination of progeny virus, even if their number were reduced.
In principle, the expression of prodrug-activating enzymes from a late viral promoter, to delay their expression until after the onset of DNA synthesis, could limit the extent to which prodrug activation depresses the virus yield. 34, 35 However, if infection of nearby cells was asynchronous, viral replication might still be inhibited through a 'bystander effect', due to local spread of activated prodrug from cells that were later in the infection cycle and thus contained sufficient activating enzyme. Furthermore, from a safety viewpoint, such vectors have the disadvantage that the transgene could be transmitted to a fully replicationcompetent virus by homologous recombination.
The E1B-55K-deleted adenoviruses are considerably attenuated relative to Ad5-WT even in permissive cancer cells, an effect that may be due to the role of E1B-55K in viral late RNA transport. 36 Wildner and Morris 37 found that expression of E1B-55K improved the oncolytic activity of their HSV-TK-expressing vectors; however, combination with GCV now decreased the antitumour efficacy, apparently due to interference with viral replication. In another study, expression of HSV-TK in an adenovirus with a WT E1 region did further delay growth of glioma xenograft tumours and prolonged survival in combination with GCV, compared with the virus alone. 35 Because these viruses expressed the full complement of WT E1 genes in a nonrestricted manner, their replication is less selective for cancer cells than E1B-55K-deleted adenoviruses raising potential safety issues. However, natural adenovirus infections are generally controlled effectively by the immune system, and the expressed HSV-TK gene would allow termination of replication in vivo with GCV, if viral replication outside the tumour approached dangerous levels. Heise et al 38 demonstrated that an adenovirus with a deletion of the pRB binding pocket of E1A is at least as oncolytic as Ad5-WT in cancer cells but markedly attenuated in normal cells, while adenoviruses in which expression of WT E1 proteins is controlled by tumour-specific promoters could be as oncolytic as WT virus in cancer cells but as replication defective as E1-deleted viruses in all normal cells, depending upon the selectivity provided by the promoter. [39] [40] [41] Thus it is clear that replicating vectors can deliver greater therapeutic efficacy than replication-defective vectors for virus-directed enzyme prodrug therapy. While in principle the ideal oncolytic virus might be fully efficacious as a single agent, multiple enzyme-prodrug combinations have been shown to enhance the overall efficacy in a number of experimental models, as anticipated from the therapeutic benefit of combining multiple agents in conventional cancer therapy. Owing to both direct cell kill and the bystander effect from prodrug activation, such combination therapy may help to overcome limitations on oncolytic vectors in cancer patients due to heterogeneity in the infectability of tumour cells or eventual termination of virus spread due to immune or other mechanisms.
Materials and methods

Cells
Human colorectal carcinoma cell lines SW480 and WiDr, primary human skin fibroblast (KS) 42 and 911 cells (human embryonic retinoblast transformed with adenovirus E1 region) 43 were cultured in DME/HEPES with 10% of fetal calf serum and 2 mM glutamine. AC-3 keratinocytes (a subclone of SCC12F that is immortalized but otherwise retains the growth characteristics of normal cells) 44 were cultured in DME/HEPES containing 5% fetal calf serum, 2 mM glutamine and 0.4 mg/ml hydrocortisone. All cells were kept at 371C in a humiditycontrolled incubator with 5% CO 2 . Antibiotics were used routinely, including penicillin (100 IU/ml) and streptomycin (100 mg/ml).
Viruses
CTL102 is an E1-deleted, replication-defective adenovirus that expresses NTR from the CMV promoter, 23 and was kindly provided by ML Laboratories plc., Keele, Staffordshire, UK. The structure of CRAd-NTR(PS1217H6) is shown in Figure 1 . Like CTL102, it is based on our earlier E1, E3-deleted Ad5 vectors; 20, 23, 45 sequences between the SacII site at bp 358 and 2321 containing E1 and the E1B-19K gene were derived from dl1520, except that the XbaI site within E1A was silently mutated to facilitate later cloning steps. This was separated from the CMV-NTR expression cassette by a 296 bp fragment containing the 3 0 end of the bovine growth hormone gene, derived from pcDNA3 (Invitrogen). Viruses were generated from plasmid DNA, propagated and plaque-titrated using 911 cells. Virus stocks were purified by caesium chloride density gradient centrifugation.
Quantitating virus replication
Replication of adenovirus DNA in vitro was monitored by dot blotting. Cells were infected with CRAd-NTR(PS1217H6) or CTL102 at a dose of 0.5 PFU/cell. At various times up to 5 days, DNA extraction was performed by the method of Hirt. 46 The DNA samples were transferred to a positively charged nylon membrane and detected by hybridization with a radioactive a-32 P-dCTP-labelled DNA probe, containing bp 31 994-34 930 of Ad5-WT. Image collection and quantitation were performed by exposing the blot for 2 h to a storage phosphor screen, which was then read using a Typhoon 8600 Variable Mode Imager (Molecular Dynamics, High Wycombe, UK). Calibration was performed using a plasmid standard.
To monitor replication of infectious virus particles in vitro, SW480 or WiDr cells (1 Â 10 5 cells per 6 cm dish)
were infected with CRAd-NTR(PS1217H6) or CTL102 (10 PFU/cell) and harvested at intervals over 4-5 days. Virus particles were released by three rounds of freezing and thawing, and the titre of infectious viral particles was determined by plaque assay on 911 cells. Quantitative polymerase chain reaction (Q-PCR) was performed to quantitate adenoviral DNA in freshly resected tumours. The oligonucleotide sequences of the DNA probe, forward and reverse primers were within the adenovirus type 5 fibre gene. Primers and probe within E1A were used to monitor stocks of the E1-deleted CTL102 virus for contamination. Samples were analysed using an ABI Prism s 7700 Sequence Detector and software (Applied Biosystems).
Analysis of NTR expression
Protein samples were prepared from cells cultured in 6 cm dishes by washing with PBS, then harvesting in 300 ml of lysis buffer (20 mM Tris-HCl pH 7.6, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 0.5% Triton X-100, 10 mg/ml each of aprotinin and leupeptin (Sigma)). Protein concentrations were determined using Bio-Rad protein assay solution (BioRad Laboratories, Mü nchen, Germany).
Protein and DNA samples were prepared from tumour tissue using TRIzol s Reagent (Invitrogen) according to the manufacturer's instruction.
To detect NTR expression, 50 mg (from cultured cells) or 100 mg (from tumours) protein sample per well was fractionated by SDS-PAGE and transferred to nitrocellulose membranes. NTR was detected using a polyclonal sheep anti-NTR antibody (kindly provided by ML Laboratories plc., Keele, Staffordshire, UK) diluted 1:20 000 and a donkey anti-sheep antibody conjugated with horseradish peroxidase (Sigma) diluted 1:2000. As a control, actin was detected using mouse anti-human aactin antibody diluted 1:5000 (Sigma), followed by a peroxidase-conjugated goat anti-mouse antibody diluted 1:1000 (DAKO).
Combination cytotoxicity assay
A total of 5000 cells per well were plated in a 96-well plate. The next day, cells were counted and infected with CRAd-NTR(PS1217H6) or CTL102, or mock-infected for 2 h. At 48 h after infection, cells were exposed to various concentrations of CB1954 (kindly provided by ML Laboratories plc., Keele, Staffordshire, UK) for 4 days, before determination of cell viability using the MTS cytotoxicity assay (CellTiter 96 s Aqueous One Solution Cell Proliferation Assay kit, Promega, Madison, WI, USA).
In situ analysis of NTR expression and virus replication in colorectal cancer xenografts All experimental procedures using animals were performed under the authority of UK Home Office Project and Personal licences, and with institutional ethical committee approval. Tumours were seeded in immunodeficient Balb/C nude mice aged 6-8 weeks, by injecting 5 Â 10 6 SW480 colon carcinoma cells subcutaneously into the flank. When the tumours reached 5-8 mm diameter, they were injected with CRAd-NTR(PS1217H6) or CTL102 (1 Â 10 8 PFU in 40 ml) by single injection, then resected at selected time points, fixed in formalin, Oncolytic adenovirus expressing nitroreductase M-J Chen et al paraffin-embedded and sectioned at 3 mm thickness. The immunostaining for NTR protein was as described previously, 22 with the addition of an initial antigen retrieval step involving microwaving the samples at 800 W in 1 l citrate buffer (pH 5.8) for 20 min. NTR was detected using polyclonal sheep anti-NTR antibody (diluted 1:2000 in PBS) at room temperature for 1 h and with a secondary, rabbit anti-sheep antibody (Vector Laboratories, Burlingame, CA, USA) diluted 1:200 in PBS, at room temperature for 30 min. This was followed by incubation with ABC mixture and AEC mixture to develop colour (Vector Laboratories). Finally, counterstaining was performed using Mayer's haematoxylin dye. Adenovirus capsid proteins were detected using rabbit anti-Ad5 antibody. 47 For detection of viral DNA by Q-PCR, or NTR by Western blotting, the tumours were grown as above but injected once with 2 Â 10 8 PFU of the viruses.
Therapeutic colorectal cancer model
Balb/C nude mice were seeded with SW480 tumours as above. When the tumours reached 5-8 mm diameter, the mice were assigned at random to receive intratumoral injection of CRAd-NTR(PS1217H6), CTL102 or vehicle (PBS). Tumours were injected with virus or PBS on 5 consecutive days, 2 Â 10 8 PFU per 40 ml injection with each injection in a different direction in order to maximize the distribution of virus within the tumours. At 48 h after the last virus injection, half the animals in each group were assigned to receive either PBS (200 ml/ day) or CB1954 (25 mg/kg/day) for 4 consecutive days, by intraperitoneal injection. Each of the treatment groups contained seven mice. Tumour size was measured twice per week with callipers and the volume was estimated by the formula: volume ¼ width 2 Â length/2.
